Neurodegenerative disease biomarkers based on high quality wireless EEG.

Objetivo

The need: Today, although over 6M people suffer from Parkinson's and related diseases worldwide we have no objective early diagnostic test. By the time patients present the symptoms that lead to diagnosis the disease is already very advanced and the options for treatment extremely limited. This has an enormous impact on cost of care and an even greater impact on patient and carer quality of life. An early diagnostic test will revolutionise treatment in terms of slowing disease evolution and improved outcomes, with fewer years in the advanced phases of the disease requiring expensive full-time care.
Our goal: We aim to commercialise non-invasive, very low-cost preclinical electroencephalograph (EEG) biomarkers for synucleinopathies (Parkinson Disease - PD and Lewy Body Dementia - LBD), which will have real impact on both quality of life and cost of care.

Ámbito científico

• ciencias sociales › economía y empresa › gestión y empresas › modelo de negocio
• ciencias médicas y de la salud › medicina básica › neurología › demencia
• ciencias médicas y de la salud › medicina básica › neurología › parkinson

Programa(s)

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
• H2020-EU.3.1.3. - Treating and managing disease

Tema(s)

• PHC-12-2014-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices

Convocatoria de propuestas

H2020-SMEInst-2014-2015

Consulte otros proyectos de esta convocatoria

Convocatoria de subcontratación

H2020-SMEINST-1-2014

Régimen de financiación

SME-1 - SME instrument phase 1

Coordinador

STARLAB BARCELONA SL

Aportación neta de la UEn

€ 50 000,00

Dirección

Avenida Tibidabo 47 Bis
08035 Barcelona
España

Región

Este › Cataluña › Barcelona

Tipo de actividad

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Enlaces

Otras fuentes de financiación

€ 21 429,00